Development Activities at Shionogi Inc.

Compound

Phase I

Phase II

Phase III

Filing

Approved

hs hs hs hs hs hs hs hs hs hs hs hs hs hs hs

S-707106 (Type-2 diabetes)

S-234462 (Obesity)

S-349572/S-265744/S-247303 (HIV infection)*

S-265744 LAP Injection (HIV infection)*

S-297995 (Alleviation of opioid-induced adverse effects)

S-117957 (Neuropathic pain)**

Ospemifene (Postmenopausal vaginal atrophy)

PSD502 (Premature ejaculation)

S-888711 (Thrombocytopenia)

S-555739 (Allergic rhinitis)

Metabolic Syndrome

Infectious Disease

Pain

Women's Health/ Sexual Dysfunction

Pediatrics

Other Areas

Compound

S-707106

Mechanism:

Insulin sensitizer

Therapeutic area:

Type 2 Diabetes

Development phase:

Phase 2

Origin:

Shionogi Discovered

Clinical trial information: click here

Compound

S-234462

Mechanism:

NPY Y5 receptor antagonist

Therapeutic area:

Obesity

Development phase:

Phase 1

Origin:

Shionogi Discovered

Compound

S-349572/S-265744/S-247303*

Mechanism:

Integrase inhibitor

Therapeutic area:

HIV infection

Development phase:

Phase 3

Origin:

Shionogi-ViiV Healthcare LLC

Compound

S-265744 LAP injection*

Mechanism:

Integrase inhibitor

Therapeutic area:

HIV infection

Development phase:

Phase 1

Origin:

Shionogi-ViiV Healthcare LLC

Compound

S-297995

Mechanism:

Peripheral receptor agonist

Therapeutic area:

Alleviation of opioid-induced adverse effects

Development phase:

Phase 2

Origin:

Shionogi discovered

Clinical trial information: click here

Compound

Ospemifene

Mechanism:

Selective estrogen receptor modulator

Therapeutic area:

PM Vaginal atrophy

Development phase:

Phase 3

Origin:

In-licensed

Compound

PSD502 (lidocaine/prilocaine)

Mechanism:

Topical anesthetics

Therapeutic area:

Premature ejaculation

Development phase:

Phase 3

Origin:

In-licensed

Compound

S-888711

Mechanism:

Thrombopoietin receptor agonist

Therapeutic area:

Thrombocytopenia

Development phase:

Phase 2

Origin:

Shionogi discovered

Clinical trial information: click here,

Compound

S-555739

Mechanism:

PGD2 receptor antagonist

Therapeutic area:

Allergic rhinitis

Development phase:

Phase 1

Origin:

Shionogi discovered

Compound

S-117957

Mechanism:

Analgesic agent for neuropathic pain

Therapeutic area:

Neuropathic pain

Development phase:

Phase 1

Origin:

Shionogi/Purdue Pharma L.P.

* Compounds marked by * are being developed through Shionogi-ViiV Healthcare LLC, a joint venture that Shionogi Inc. supports.
** Compound marked by ** is being co-developed through Shionogi & Co., Ltd. and Purdue Pharma L.P. that Shionogi Inc. supports.

This pipeline presentation contains general information about Shionogi's products in development. The development activities include many aspects which we have not attempted to capture in this high-level overview. Investors should be aware that many factors, some of which are beyond the control of the company, can impact the feasibility and commercial value of each development project, and the portfolio as a whole.